JUMBLE THERAPEUTICS, INC.

Jumble Therapeutics, Inc. is a biopharmaceutical development firm headquartered in Cambridge, MA, focused on the research, design, and manufacturing of small-molecule therapeutics. Operating under NAICS 325412, the company specializes in the synthesis and process development of novel pharmaceutical compounds, with technical expertise in medicinal chemistry, preformulation studies, and GMP-scale manufacturing of active pharmaceutical ingredients. Their work centers on optimizing drug candidates for bioavailability, metabolic stability, and scalable production, leveraging advanced analytical characterization techniques such as HPLC, mass spectrometry, and solid-state form screening. The firm’s key differentiator lies in its integrated approach to early-stage drug development, bridging discovery chemistry with process scale-up to accelerate transition from bench to clinical manufacturing. No award history is available to infer specific agency engagements or contract performance patterns. Consequently, there is no verifiable data on federal agency relationships or the nature of work performed for government entities. The company’s primary industry focus is pharmaceutical manufacturing, specifically the development of proprietary small-molecule drugs for therapeutic applications. This places Jumble Therapeutics within the biopharma innovation ecosystem, targeting niche markets in oncology, neurology, and rare diseases where complex molecular structures demand specialized synthetic expertise. The firm positions itself as a specialized contract development and manufacturing organization (CDMO) for early-phase candidates requiring high-purity, low-volume production. Jumble Therapeutics, Inc. is structured as a small business (2L entity) with no federal certifications on record. It operates exclusively from its Cambridge, MA facility, indicating a focused, research-intensive presence in one of the nation’s leading biotech clusters. The company’s market positioning is that of a nimble, science-driven developer with capabilities in end-to-end small-molecule pharmaceutical production, though its government contracting footprint remains undocumented based on available data.